Genscend Biopharmaceutical

Genscend Biopharmaceutical is a clinical-stage biotechnology company based in Tianjin, China, specializing in the development of innovative anti-angiogenic therapies for cancer and vascular disorders. Founded by Dr. Lu-Yuan Li, the company leverages advanced research in vascular biology to create recombinant protein therapeutics designed to inhibit tumor growth by disrupting their blood supply. Its lead program, GS-101, is a modified recombinant human endostatin that has been investigated in clinical trials for the treatment of various solid tumors. Beyond oncology, the company's research extends to neovascular eye diseases, aiming to address significant unmet needs in ophthalmology through its protein engineering capabilities. Genscend maintains close ties with academic research institutions to drive its drug discovery and development pipeline.